Telegram RegisterThe public register of Telegram
Telegram profile photo for [신한 리서치본부] 제약/바이오

Channel

[신한 리서치본부] 제약/바이오

@bio_shinhan

On this record: Topic · Observations · Also posting the same content · Growth · Engagement · Posts · Posts edited after publishing · Citations · Cite this entry

21,437subscribers

+195 since we began measuring on 6 August 2026

Risers and fallers across the register · movement among entries of 10,000–31,623.

Register entry

Telegram ID-1001604473784
TypeChannel
Username@bio_shinhan
CreatedBetween 1 December 2021 and 30 April 2023 — estimated from Telegram’s id allocation, not measured. How this range is calculated.
First recorded6 August 2026
Last confirmed live17 September 2026
Measurements held30
Confirmed unchanged1 time, most recently 17 September 2026
On Telegramt.me/bio_shinhan

Topic

Other / unclassifiable — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-UD-Q6_K_XL, prompt version 1) read this channel’s own recent posts on 10 August 2026 and assigned it the closest of 31 fixed categories, at 66% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.

Observations

These are measurements, not verdicts. Each one below states something we counted, alongside the evidence it was counted from, so you can check it rather than take it. None of them is graded: every observation this register holds is recorded at severity 0, because the precision of the detectors behind them has not been measured yet, and a rating we cannot support is worse than none. Read each as a fact about the data, not as a judgement about the channel. How we measure.

Content that also appears on other registered channels

Posts published here appear word for word on 2 other registered channels. The matching is on the text itself, not on Telegram’s forward marker, so it finds a copy whether or not it was labelled as one.

Matching posts — open both and compare (4 of the pairs behind the counts below)
Posted firstThenOverlapGap
@bio_shinhan/4664 · this entry4 Aug 2026, 11:01 UTC@SmartnGrowth/5744 Aug 2026, 11:02 UTC1.0072 seconds
@SmartnGrowth/5794 Aug 2026, 22:55 UTC@bio_shinhan/4668 · this entry4 Aug 2026, 23:46 UTC1.0050 minutes
@alteogenIR/25130 Jul 2026, 23:08 UTC@bio_shinhan/4655 · this entry30 Jul 2026, 23:31 UTC1.0023 minutes
@alteogenIR/25431 Jul 2026, 05:31 UTC@bio_shinhan/4657 · this entry2 Aug 2026, 22:49 UTC1.003 days
Every channel this entry shares post bodies with
ChannelMatching postsText overlapTypical gapPublished first
@SmartnGrowth6 (6/6 hand-verifiable sample passed)1.003 minuteseven
@alteogenIR6 (6/6 hand-verifiable sample passed)1.0037 minutes@alteogenIR (51)

Text overlap is the Jaccard coefficient over the set of distinct three-word phrases in the two bodies: 1.00 is identical wording, and the threshold for counting a pair at all is 0.70. Candidates are generated by simhash LSH (4 x 16-bit bands, exact Hamming <= 3) verified against the bodies with Jaccard over the SET of distinct 3-word shingles. Published first counts which side of each matching pair carries the earlier timestamp — in this corpus, which is the limitation directly below.

What this cannot establish

MEASURED, DOMINANT ERROR SOURCE: a post ingested before 2026-08-06 may have carried a forward header that was not recorded. A 45-pair hand-check against live t.me pages found 14 (31%) where the live page shows a forward header naming the other channel and the database has none, plus 4 more (9%) naming a third party. The text match itself was wrong 0 times out of 45. Read attribution_capture.items_in_trusted_window before treating the unattributed count as a claim.

Telegram lets a channel forward a post with a header naming the source, and we only began reliably recording that header on 2026-08-06. None of the 2 matches recorded here fall after that date, so for this entry we cannot say whether any of them carried a credit. The duplication is measured; the absence of attribution is not.

“Published first” means first in this corpus. We hold 21 comparable posts for this entry, running 30 July 2026 to 7 August 2026. A channel we have read one page deep will look younger than a neighbour we have read in full, and the order would flip with no change in the underlying facts.

The detector’s own notes on this observation, as it recorded them. Names in this_style are fields of the underlying evidence record, which the plain-English paragraphs above read out for this entry.

  • Verbatim republication has three causes and the text separates only two: a clone/mirror, unattributed copy-paste, or BOTH channels copying a common third source that neither attributes. The spread filter (content held by at most 8 channels) reduces the third and does not remove it.
  • 'Earliest' means earliest IN THIS CORPUS. A channel ingested one page deep will look younger than a neighbour ingested in full; corpus_coverage above is there to be checked before the direction is believed.
  • shared_verified_est extrapolates the sampled pass rate over the full narrow match count; sampled/passed are the numbers actually measured.
  • Absence of a forward header is not proof of intent: Telegram lets a channel disable forward attribution, and a credit written in the body is not parsed as attribution here (mention_edge_either_way above is the closest available signal).

Across the whole group of 3, the earliest publisher we hold is @alteogenIR. That is a statement about our reading window, not a claim of authorship.

Recorded under the keys clone_copy · clone_mutual, last confirmed 7 August 2026. An observation that a later pass no longer finds is cleared, and a cleared observation is removed from this page rather than being shown struck through — we do not keep publishing a claim we have withdrawn. Dispute an observation.

Also posting the same content

This channel’s posts match, word for word or near enough, posts on 2 other registered channels, found by comparing text fingerprints across every channel on the register. That matching has been checked by hand against the live Telegram pages and found reliable — 0 wrong of 45 pairs re-read.

Which channel, if either, published first is deliberately not shown. The same hand-check found that reading wrong 18 of 45 times — 60%, no better than a coin flip — because it depends on how deep our own crawl happened to reach into each channel’s history, not on when the content was actually first posted. This list is ordered by subscriber count, the same as every other listing on this site, never by which channel we think came first. Word-for-word matching has several ordinary explanations besides copying — a channel mirroring itself, an unattributed repost, or two channels independently repeating the same wire story — and this measurement cannot tell those apart. How this is measured.

Growth

21,22421,43721,330.56 August 2026 — 21,242 subscribers6 August 2026 — 21,241 subscribers7 August 2026 — 21,236 subscribers8 August 2026 — 21,235 subscribers9 August 2026 — 21,237 subscribers10 August 2026 — 21,246 subscribers13 August 2026 — 21,244 subscribers15 August 2026 — 21,242 subscribers17 August 2026 — 21,241 subscribers18 August 2026 — 21,234 subscribers19 August 2026 — 21,224 subscribers20 August 2026 — 21,247 subscribers21 August 2026 — 21,244 subscribers23 August 2026 — 21,304 subscribers24 August 2026 — 21,330 subscribers26 August 2026 — 21,332 subscribers26 August 2026 — 21,333 subscribers28 August 2026 — 21,332 subscribers28 August 2026 — 21,330 subscribers30 August 2026 — 21,326 subscribers1 September 2026 — 21,341 subscribers2 September 2026 — 21,334 subscribers3 September 2026 — 21,351 subscribers4 September 2026 — 21,350 subscribers7 September 2026 — 21,353 subscribers10 September 2026 — 21,338 subscribers12 September 2026 — 21,395 subscribers14 September 2026 — 21,398 subscribers15 September 2026 — 21,432 subscribers17 September 2026 — 21,437 subscribers6 August 202617 September 2026
30 measurements spanning 43 days, net +195. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 21,192–21,469 and does not start at zero.
Measurement log — every subscribers count we have recorded, most recent 20 of 30
Measured (UTC)SubscribersChange
17 Sept 2026, 21:3821,437+5
15 Sept 2026, 21:5521,432+34
14 Sept 2026, 08:0021,398+3
12 Sept 2026, 19:1721,395+57
10 Sept 2026, 21:5821,338-15
7 Sept 2026, 20:1621,353+3
4 Sept 2026, 23:3621,350-1
3 Sept 2026, 09:4721,351+17
2 Sept 2026, 01:2421,334-7
1 Sept 2026, 02:0821,341+15
30 Aug 2026, 01:1521,326-4
28 Aug 2026, 22:0721,330-2
28 Aug 2026, 00:4821,332-1
26 Aug 2026, 22:3321,333+1
26 Aug 2026, 00:3421,332+2
24 Aug 2026, 21:2721,330+26
23 Aug 2026, 08:2521,304+60
21 Aug 2026, 20:3421,244-3
20 Aug 2026, 19:0521,247+23
19 Aug 2026, 20:1221,224first reading

Engagement

91 posts held, back to 30 July 2026the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 58 pages of Telegram’s post history, 20 posts per page.

ERR · 30 days
31.4%
avg views ÷ 21,437 subscribers
Avg views / post
6,730
27 posts measured
Reaction rate
this channel exposes no reaction counts
Posts in window
27
of 91 held

ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.

ER is defined industry-wide as (forwards + reactions + comments) ÷ views — note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.

What these figures were computed from
WindowRolling 30 days · latest post in window 2 September 2026
Posts held91 (30 July 20262 September 2026)
Views total181,770
Reactions total
Forwards / commentsnot exposed by the public surface — not measured, not estimated
Readings taken3 Sept 2026, 16:41 UTC

Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.

Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.

Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.

Recent posts

2 Sept 2026, 22:33 UTC≈36,700 viewsread 3 September 2026

『알테오젠(196170.KQ) - 세계 최초 유전자 치료제 SC, 서프라이즈』 기업분석부 엄민용, 이호철 ☎️ 02-3772-1546 ▶️ 신한생각: 전세계 최초 유전자 치료제 SC 개발, 노바티스와 간다 노바티스와 4.4조원 규모 메가딜 체결. 벌써 올해만 4건 L/O 성공했고 하반기 추가 딜 지속 목표. 이번 딜의 의미는 전세계 최초로 AOC* 형태 IV 유전자 치료제를 SC로 전환하기 위해 알테오젠과 손 잡은 것. 다른 글로벌 유전자 치료제 기업들에 SC 전환의 필수성을 각인할 계약이라는 점이 중요. 단기 트레이딩 관점 접근은 적절치 않으며, 가치 변화에 집중 권고 ▶️ 도대체 얼마나 보여줘야? 누적 규모 16조원, 파트너사 10곳, 31개 품목 계약금 비공개지만 3월 바이오젠 L/O 당시 1품목 당 계약금 300억원 및 물질 추가될

2 Sept 2026, 22:29 UTC≈3,500 viewsread 3 September 2026

✅ 2026.09.03(목) 바이오/제약 주요 뉴스 알테오젠, 노바티스와 4.4조원(32.2억달러) 규모 L/O 계약으로 올해만 4번째 체결…글로벌 제약사 10곳과 누적 계약규모 16조원 이상, 기존과 다른 신규 모달리티 적용 가능성 언급되며 ALT-B4 상업성 확장 순항 https://www.thebionews.net/news/articleView.html?idxno=27745 할로자임 ‘엠다제’ 특허 잇단 무효로 MSD ‘키트루다SC’·알테오젠 특허 리스크↓...美 PTAB, ‘520 특허’ 심판 대상 청구항 모두 특허 불능 판단하며 MDASE 관련 다섯 번째 무효, 미국 특허 분쟁 MSD/알테오젠에 승기 https://www.thebionews.net/news/articleView.html?idxno=27743 미국 메디케어 비만

2 Sept 2026, 22:09 UTC≈15,400 viewsread 3 September 2026
Photo

미국 바이오 지수 NBI 3일 연속 상승 중 MSD, 노바티스도 역사적 신고가 수준 근접 MSD는 지난 5월 할로자임 특허 승소 및 키트루다SC 빠른 성장, 모더나 mRNA 항암 백신 성공해 역사적 신고가 어제 알테오젠과 계약한 노바티스도 2025년 10월 Avidity 16.4조원 인수 발표 후 지속 상승해 역사적 신고가 후 다시 근접 중

2 Sept 2026, 11:25 UTC≈3,830 viewsread 3 September 2026
Forwarded from @alteogenIR

안녕하세요. 금일 체결한 노바티스 라이선스 계약에 대해 해외 배포한 영문기사 공유드립니다. https://finance.yahoo.com/healthcare/articles/alteogen-enters-option-license-agreement-110000294.html

2 Sept 2026, 04:32 UTC≈2,160 viewsread 3 September 2026
Forwarded from @alteogenIR

안녕하세요. 알테오젠이 글로벌 Top-tier 제약사 노바티스(Novartis)와 올해 4번째 하이브로자임 플랫폼 기술 라이선스 계약을 체결하였습니다. 이번 계약의 총액은 32억 2,300만 달러(한화 약 4조 4,165억 원)로 노바티스는 복수의 바이오의약품에 대해서 ALT-B4를 활용한 피하주사 제형 개발 및 상업화할 수 있는 독점적 권리를 확보하게 됩니다. 이를 통해 하이브로자임 플랫폼의 라이선스 파트너 기업은 총 10개사(MSD, Sanofi, AstraZeneca, Novartis, GSK, Biogen, Daiichi Sankyo, Sandoz, Intas, 비공개 파트너)로 확대되었습니다. 노바티스는 당사와 라이선스 계약에 앞서 다양한 모달리티(modality)에 ALT-B4를 적용한 피하주사 제형 전환에 대한 평가를 수행해

2 Sept 2026, 04:27 UTC≈2,730 viewsread 3 September 2026
Forwarded from @darthacking

2026.09.02 13:26:34 기업명: 알테오젠(시가총액: 21조 10억) A196170 보고서명: 투자판단관련주요경영사항 (재조합 인간 히알루로니다제 제품 ALT-B4 독점적 옵션·라이선스 계약 체결) 제목 : 재조합 인간 히알루로니다제 제품 ALT-B4 독점적 옵션·라이선스 계약 체결 * 주요내용 ※ 투자유의사항 본 계약은 의약품규제기관의 허가가 완료되어야 이행되는 조건부 계약으로서, 본 계약을 통한 수익 인식은 임상시험과 품목허가 등의 성공 여부에 따라 달라질 수 있습니다. 계약 조건에 따라, 규제기관에 의한 연구 개발의 중단, 품목허가 실패 등 발생시 계약이 해지될 수 있습니다. 1. 계약상대방: Novartis Pharma AG (스위스) - Novartis 최근 사업연도(2025) 매출액: $54

2 Sept 2026, 02:09 UTC≈1,800 viewsread 3 September 2026
Forwarded from @alteogenIRPhoto

안녕하세요. 파트너사 MSD(미국·캐나다 내 Merck)가 할로자임(Halozyme)의 MDASE 관련 특허를 상대로 제기한 특허무효심판(PGR)에서 미국 특허청은 또다시 할로자임의 특허가 무효라는 결정을 내렸습니다. 이번 결정은 MSD가 제기한 다수의 PGR 가운데 또 하나의 최종결과(Final Written Decision)로, 대상 특허는 할로자임의 미국 등록특허 12,110,520입니다. 미국 특허심판원(Patent Trial and Appeal Board)은 해당 특허의 심판 대상 청구항 전부가 written description(서면기재요건)과 enablement(실시가능요건)을 충족하지 못한다고 판단했습니다. 이로써 할로자임은 미국에 등록한 MDASE 관련 특허에 대해 다섯 번째 무효 결정을 받게 되었습니다. (특허 번호

1 Sept 2026, 23:00 UTC≈4,400 viewsread 3 September 2026

✅ 2026.09.02(수) 바이오/제약 주요 뉴스 [WCLC 2026] 보로노이, WCLC 의장 안명주 교수 Mini oral 세션에서 VRN11(EGFR 변이 비소세포폐암 표적 치료제)·VRN10(HER2 표적 치료제) 임상·전임상 데이터 발표 예정...포스터 포함해 VRN11 4건·VRN10 2건 등 핵심 파이프라인 연구 총 6건 공개 https://www.thebionews.net/news/articleView.html?idxno=27689 다이이찌 산쿄/AZ 엔허투(HER2 타깃 ADC), EU서 퍼투주맙(HER2 항체) 병용요법 HER2 유방암 1차 치료 진입하며 미국 이어 유럽에서도 초기 처방 확보…엔허투SC 공동개발 중인 알테오젠 ALT-B4, ADC SC 전환 이점 추가 확대 의의 https://www.thebionews.

1 Sept 2026, 07:49 UTC≈3,220 viewsread 3 September 2026
Forwarded from @darthacking

2026.09.01 16:23:44 기업명: 유한양행(시가총액: 6조 880억) A000100 보고서명: 단일판매ㆍ공급계약체결 계약상대 : 글로벌 제약사 계약내용 : ( 상품공급 ) 원료의약품(API) 공급계약 공급지역 : 미정 계약금액 : 1,311억 계약시작 : 2026-09-01 계약종료 : 2028-05-31 계약기간 : 1년 9개월 매출대비 : 6.0% 공시링크: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260901800500 최근계약 : https://www.awakeplus.co.kr/board/contract/000100 종목공시 : https://www.awakeplus.co.kr/disclosure/000100

31 Aug 2026, 23:04 UTC≈5,290 viewsread 3 September 2026

✅ 2026.09.01(화) 바이오/제약 주요 뉴스 알테오젠, ‘키트루다SC’ 판매 마일스톤 총 10억달러 중 1번째 마일스톤인 2,500만달러 수령…키트루다SC 올해 상반기 5.9억달러(8,121억원) 매출로 4월 J-code 발급 이후 빠른 성장세, 암 백신 병용 등 신규 활용방안 등장하며 매출 지속 성장 전망 https://www.thebionews.net/news/articleView.html?idxno=27655 셀트리온, 1,000억원 규모 52만 4,384주의 자사주 매입하며 올해 누적 3,000억원 매입…매입에서 소각까지 연계 예정, 매년 순이익 3분의 1 주주환원 https://www.medipana.com/news/articleView.html?idxno=416798 삼성바이오로직스, 최대 2.7조원 규모로 폴리펩타이드

31 Aug 2026, 03:10 UTC≈2,610 viewsread 3 September 2026
Forwarded from @alteogenIR

안녕하세요. 알테오젠이 파트너사 MSD로부터 $25m(약 344억원)의 판매 마일스톤을 수령한다고 공시했습니다. 이번 판매 마일스톤은 파트너제품 Keytruda Qlex의 매출에 따라 첫 번째로 수령하는 Sales milestone이라는 의미가 있습니다. MSD는 올해 상반기 $590m(약 8,121억원)의 Keytruda Qlex 매출을 올렸다고 밝혔고, 내년까지 키트루다의 30~40%를 SC로 전환하는데 자신하고 있습니다. 자세한 내용은 아래 링크를 통해 확인해주시기 바랍니다. - 공시링크: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260831900176 - PR링크 : https://alteogen.com/kr/sub/ir/news.php?mode=view&bid=1&idx=357&page=

31 Aug 2026, 03:10 UTC≈4,600 viewsread 3 September 2026
Forwarded from @darthacking

2026.08.31 11:25:47 기업명: 셀트리온(시가총액: 43조 2,901억) A068270 보고서명: 주요사항보고서(자기주식취득결정) * 보통주 취득수량 : 524,384주(1,000억) 시총대비 : 0.23% * 우선주 취득수량 : (-) 시총대비 : 취득목적 : 주가 안정 및 주주가치 제고 취득방법 : 유가증권시장을 통한 장내 매수 중개업자 : NH투자증권(NH INVESTMENT & SECURITIES CO., LTD.) 결정일자 : 2026-08-31 공시링크: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260831000538 과거공시 : https://www.awakeplus.co.kr/disclosure/068270

Showing the 12 most recent of 91 posts we hold for @bio_shinhan. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.

Posts edited after publishing

@bio_shinhan edited 3 posts after it first published — the same permalink now carries different wording than the one this register originally read, caught because our own crawl held a copy of the earlier text.

An edit is not deception. Typo fixes, price updates and corrections look exactly like this too — this register can tell you the wording changed and when, not why. How this is measured.

First edit seen
13 August 2026
Most recent edit
28 August 2026

Forward network

Republished by

Channels on the register that have forwarded this channel's posts into their own feed.

Yeouido Lab_여의도 톺아보기
@Yeouido_Lab · 43,309
8 posts
팔칠사공스토너 실전투자 인사이트
@stoner8740 · 11,035
7 posts
돼지바
@bbong_tta · 12,711
4 posts
인상주의 투자 인생 업그레이드노트
@insangnism · 11,308
4 posts
텐렙
@Ten_level · 17,133
3 posts
🗽엄브렐라(Umbrella Research) 리서치+ 네프콘 옆집부자형 since 2020
@umbrellaresearch · 12,852
3 posts
조기주식회 공부방
@EarlyStock1 · 24,432
2 posts
지아이이노베이션 공식 IR
@GIInnovation · 2,090
2 posts
현업자의 맘대로 겜투일지
@Game2diarychannel · 555
2 posts
알테오젠 IR
@alteogenIR · 9,800
2 posts
제약/바이오/미용 원리버 Oneriver
@pharmbiohana · 29,843
2 posts
LSKP CFO의 개인 공간❤️
@valuecore · 1,090
2 posts
MJ의 Bio & Healthcare
@BarbarianBHC · 4,955
1 post
오를주식 - 뉴스/경제/주식
@GoUpstock · 20,978
1 post
[IV Research]
@IVResearch · 2,473
1 post
MYCloud Partners
@MycloudPartners · 1,030
1 post
스마트앤그로스 (Smart & Growth)
@SmartnGrowth · 3,309
1 post
상장기업 수사대 ☎️
@cyber_rangers · 16,973
1 post
간절한 투자스터디카페
@desperatestudycafe · 18,824
1 post
이프로 밸류스탁
@epro_valuestock · 305
1 post
빠르고 정확한 주식정보방
@fastest_info1 · 13,219
1 post
호그니엘
@hogniel · 15,327
1 post
아이엠바이오로직스 IR/PR
@imbiologics_official · 519
1 post
김찰저의 관심과 생각 저장소
@kimcharger · 24,877
1 post
投資, 아레테
@mstaryun · 18,661
1 post
너쟁이의 성실한 추추생활
@nje2e · 8,459
1 post
힙한 펭미업의 1인칭 시점
@pengmeup · 9,129
1 post
큐리언트 스토리
@qurient · 1,460
1 post
서초동 투자머신
@twomachine · 5,303
1 post

Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.

Mentions

Named by 3 registered channels — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.

Names

Channels on the register whose handles appear in this channel's posts.

A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.

Cite this entry

A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 17 September 2026 — this entry's latest reading, not the date you are reading this.

“[신한 리서치본부] 제약/바이오” (@bio_shinhan), 21,437 subscribers as measured 17 September 2026. Telegram Register, tgregister.com/channel/bio_shinhan.

Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.